NCT05231122 - Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 12, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions

Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous AdenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Fallopian Tube Serous AdenocarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian Clear Cell AdenocarcinomaRecurrent Ovarian Endometrioid AdenocarcinomaRecurrent Ovarian Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Primary Peritoneal Clear Cell AdenocarcinomaRecurrent Primary Peritoneal Endometrioid AdenocarcinomaRecurrent Primary Peritoneal Serous Adenocarcinoma

Interventions

BIOLOGICAL

Anti-CD40 Agonist Monoclonal Antibody CDX-1140

Given IV

BIOLOGICAL

Bevacizumab

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (2)

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

77030

RECRUITING

M D Anderson Cancer Center, Houston